A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients (CLeaN)
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis|
- Improvement in Health of Skin [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Change from baseline in Eczema Area Severity Index (EASI) Score.
- Improvement in Health of Skin [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Change from baseline in Investigator Global Assessment (IGA) Score.
- Improvement in Health of Skin [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Change from baseline in Body Surface Area (BSA) Score.
- Patient satisfaction [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Quality of Life Questionnaires will be reviewed for a patient and family satisfaction.
- Decreased itching [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Visual Analog Scale will be reviewed for decrease in pruritus.
- Reduction of bacteria [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Bacterial cultures will be evaluated for decreased quantitative numbers.
|Study Start Date:||November 2012|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Staphylococcus aureus colonization and potential infection represent a common clinical finding in patients with atopic dermatitis (AD) and may contribute to exacerbation of the disease. Atopic patients are commonly colonized with S. aureus on both lesional and non-lesional skin. Antibiotic treatment of clinically infected patients can often improve the bacterial infection as well as reduce the overall severity of AD. More recently, measures to reduce S. aureus colonization have been shown to decrease the clinical severity of Atopic Dermatitis in patients with clinical signs of secondary bacterial infection of the skin.
Given the increasing incidence of recurrent skin infections caused by S. aureus, measures such as dilute sodium hypochlorite (bleach) baths have been adopted by many physicians in an effort to decrease infection rates and disease severity in patients with atopic dermatitis, recurrent impetigo, cellulitis, folliculitis, boils and abscesses. There is some controversy in the literature regarding the efficacy of anti-staphylococcal treatments in improving AD in patients without active clinical infection as one review noted limited benefit while another study showed that dilute bleach baths improved AD.
Bleach baths are widely used in pediatrics and adult medicine. A common regimen consists of adding ½ cup of household bleach into ½ tub of warm bath water, resulting in a 0.009% sodium hypochlorite concentration. (www.bleachbath.com) CLn® BodyWash contains several common surfactants to clean the skin and 0.006% sodium hypochlorite concentration for preservation, and is further diluted when lathered onto the skin with water. This over the counter product is delivered in a sealed, easy to use dispenser, which can be used in the bath or shower, lathered on and rinsed off after 1-2 minutes of skin contact. CLn® BodyWash may be a convenient alternative to bleach baths.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01714245
|United States, Illinois|
|Northwestern University, Department of Dermatology|
|Chicago, Illinois, United States, 60611|
|United States, Texas|
|University of Texas Medical School - Houston|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Adelaide A. Hebert, MD||University of Texas Medical School - Houston|